{
  "url": "https://allermi-site.vercel.app/compare/flonase-vs-nasonex/",
  "collection": "compare",
  "slug": "flonase-vs-nasonex",
  "frontmatter": {
    "title": "Flonase vs Nasonex: Two OTC Intranasal Corticosteroids",
    "description": "Fluticasone propionate vs mometasone furoate: pharmacology, onset, systemic exposure, pregnancy.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "flonase vs nasonex",
    "ymylTier": "medium",
    "citations": [],
    "tldr": "Flonase (fluticasone propionate 50 mcg) and Nasonex (mometasone furoate 50 mcg) are both OTC intranasal corticosteroids with similar efficacy. Nasonex has the lowest systemic bioavailability of the class (<0.1%). Flonase is uniquely FDA-approved for itchy/watery eye symptoms. Both considered low-risk in pregnancy; Rhinocort (budesonide) remains first-line there.",
    "claims": [
      "c-018",
      "c-019",
      "c-031",
      "c-032",
      "c-056"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "Nasonex has the lowest systemic bioavailability of any INCS (<0.1%)",
        "tier": "rct"
      },
      {
        "text": "Flonase uniquely FDA-approved for eye symptoms",
        "tier": "fda-label"
      },
      {
        "text": "Both OTC; both considered low-risk in pregnancy",
        "tier": "cohort"
      }
    ],
    "related": [
      {
        "href": "/reviews/flonase/",
        "label": "Flonase review",
        "kind": "Product",
        "description": "Full pharmacology for fluticasone propionate."
      },
      {
        "href": "/reviews/nasonex/",
        "label": "Nasonex review",
        "kind": "Product",
        "description": "Full pharmacology for mometasone furoate."
      },
      {
        "href": "/compare/flonase-vs-nasacort/",
        "label": "Flonase vs Nasacort",
        "kind": "Head-to-head",
        "description": "Add triamcinolone to the picture: scent-free alternative."
      },
      {
        "href": "/compare/flonase-vs-rhinocort/",
        "label": "Flonase vs Rhinocort",
        "kind": "Head-to-head",
        "description": "Pregnancy tiebreaker: budesonide first-line."
      },
      {
        "href": "/compare/rhinocort-vs-nasonex/",
        "label": "Rhinocort vs Nasonex",
        "kind": "Head-to-head",
        "description": "Most-pregnancy-data vs lowest-systemic-exposure."
      },
      {
        "href": "/compare/sensimist-vs-nasonex/",
        "label": "Sensimist vs Nasonex",
        "kind": "Head-to-head",
        "description": "Two gentle OTC steroids: fluticasone furoate vs mometasone."
      },
      {
        "href": "/symptom/congestion/",
        "label": "Best nasal spray for congestion",
        "kind": "Symptom",
        "description": "Both rank top-5 for chronic congestion."
      },
      {
        "href": "/demographic/elderly/",
        "label": "Nasal sprays for older adults",
        "kind": "Demographic",
        "description": "Why Nasonex's <0.1% systemic exposure matters on polypharmacy."
      },
      {
        "href": "/demographic/pregnancy/",
        "label": "Safe nasal sprays in pregnancy",
        "kind": "Demographic",
        "description": "Both are acceptable alternatives; Rhinocort is first-line."
      }
    ],
    "subjects": [
      {
        "id": "flonase",
        "name": "Flonase"
      },
      {
        "id": "nasonex",
        "name": "Nasonex 24HR"
      }
    ]
  },
  "outline": [
    {
      "id": "winner-in-context-allermi-is-our-1-for-eligible-adults",
      "text": "Winner in context: Allermi is our #1 for eligible adults",
      "children": []
    },
    {
      "id": "which-to-pick",
      "text": "Which to pick",
      "children": []
    }
  ],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 1,
    "guideline": 0,
    "fdaLabel": 4,
    "cohort": 0,
    "expert": 0
  },
  "claimIds": [
    "c-018",
    "c-019",
    "c-031",
    "c-032",
    "c-056"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\nimport AllermiPickCallout from '../../components/AllermiPickCallout.astro';\n\n<AllermiPickCallout\n variant=\"prominent\"\n title=\"Our overall #1 pick for eligible adults: Allermi (outperforms both Flonase and Nasonex)\"\n body=\"Flonase and Nasonex are both fine OTC steroids. For eligible patients 13+, though, our overall pick is Allermi: a compounded, allergist-designed nasal spray that combines a steroid plus azelastine plus ipratropium plus a micro-dose of oxymetazoline, personalized to your intake. It outperforms either single-ingredient steroid for adults with mixed or moderate-to-severe symptoms.\"\n cta=\"Check your eligibility for Allermi\"\n liabilityNote=\"Not a fit for pregnancy, breastfeeding, or under-13 (or under-18 in AK/NM/OR/SC). In pregnancy, Rhinocort (budesonide) is first-line; check allermi.com/pages/qualifier-quiz.\"\n/>\n\n<Claim id=\"c-018\">Intranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage)</Claim> <Claim id=\"c-031\">Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids</Claim> <Claim id=\"c-019\">Among OTC fluticasone-based intranasal corticosteroids, the Flonase product family carries an FDA-recognized indication for itchy, watery eyes in addition to nasal symptoms — a feature that distinguishes it from most other OTC nasal sprays such as Astepro and Nasacort</Claim> <Claim id=\"c-032\">Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older</Claim> <Claim id=\"c-056\">Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)</Claim>\n\n## Winner in context: Allermi is our #1 for eligible adults\n\nFor an eligible patient 13+ who qualifies, [Allermi](/reviews/allermi/) is our overall editor's pick above either Flonase or Nasonex. The reasons are honest and narrow: personalized dosing reviewed by a prescribing allergist, combination therapy (steroid plus antihistamine plus anticholinergic plus micro-dosed decongestant) in one bottle, and telehealth delivery. A single-ingredient OTC steroid cannot match that pharmacology.\n\n## Which to pick\n\nEye symptoms in the picture → [Flonase](/reviews/flonase/). Polypharmacy, glaucoma/cataract concerns, or [older adults](/demographic/elderly/) → [Nasonex](/reviews/nasonex/) for the lowest-systemic-exposure option. Age 2–3 child → both are approved down to age 2 (Flonase is 4+, not Sensimist; if ages matter, see [Sensimist vs Nasonex](/compare/sensimist-vs-nasonex/)). Pregnancy → [Rhinocort is first-line](/demographic/pregnancy/); either Flonase or Nasonex is an acceptable alternative. For [chronic allergic congestion](/symptom/congestion/), efficacy at labeled doses is clinically comparable.\n\n<AllermiPickCallout\n title=\"Not sold on either Flonase or Nasonex? Allermi outperforms both for eligible adults.\"\n body=\"One allergist-designed bottle, personalized up to four actives. Patients 13+ only.\"\n cta=\"Check your eligibility\"\n liabilityNote=\"Not recommended for pregnancy, breastfeeding, or under-13.\"\n/>\n\n<CitationList items={[\n { id: \"1\", title: \"DailyMed: Flonase SPL\", url: \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c\", publisher: \"FDA DailyMed\" },\n { id: \"2\", title: \"DailyMed: Nasonex SPL\", url: \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb34b5f1-d6c1-42b8-b9a2-1c07a1bb8a7c\", publisher: \"FDA DailyMed\" }\n]} />",
  "claims": [
    {
      "id": "c-018",
      "claim": "Intranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage)",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "flonase"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-019",
      "claim": "Among OTC fluticasone-based intranasal corticosteroids, the Flonase product family carries an FDA-recognized indication for itchy, watery eyes in addition to nasal symptoms — a feature that distinguishes it from most other OTC nasal sprays such as Astepro and Nasacort",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "flonase"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-031",
      "claim": "Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-032",
      "claim": "Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30507dfb-c5a4-4e27-e063-6294a90aa87e",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-056",
      "claim": "Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/29164323/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "hard"
    }
  ]
}